Clinical trial
Study of Ravulizumab in Children and Adolescents With Atypical Hemolytic Uremic…
NCT03131219 · Alexion Pharmaceuticals, Inc., Industry · Completed
Key facts
| NCT number | NCT03131219 |
|---|---|
| Title | Study of Ravulizumab in Children and Adolescents With Atypical Hemolytic Uremic Syndrome (aHUS) |
| Official title | A Phase 3, Open-Label, Multicenter Study of ALXN1210 in Children and Adolescents With Atypical Hemolytic Uremic Syndrome (aHUS) |
| Lead sponsor | Alexion Pharmaceuticals, Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Atypical Hemolytic Uremic Syndrome (aHUS) |
| Intervention type | Biological |
| Interventions | Ravulizumab |
| Enrollment | 34 |
| Start date | Aug 31, 2017 |
| Primary completion | Dec 20, 2022 |
| Completion | Dec 20, 2022 |
| First posted | Apr 27, 2017 |
| Last update posted | Mar 15, 2024 |
| Countries | Belgium, Germany, Italy, South Korea, Spain, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: